US20190083807A1 - Method for treating male sexual dysfunction by using underpants comprising far-infrared fibers - Google Patents
Method for treating male sexual dysfunction by using underpants comprising far-infrared fibers Download PDFInfo
- Publication number
- US20190083807A1 US20190083807A1 US15/709,516 US201715709516A US2019083807A1 US 20190083807 A1 US20190083807 A1 US 20190083807A1 US 201715709516 A US201715709516 A US 201715709516A US 2019083807 A1 US2019083807 A1 US 2019083807A1
- Authority
- US
- United States
- Prior art keywords
- far
- underpants
- infrared
- sexual dysfunction
- powdered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000835 fiber Substances 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims abstract description 35
- 206010057672 Male sexual dysfunction Diseases 0.000 title claims abstract description 27
- 201000001880 Sexual dysfunction Diseases 0.000 claims abstract description 23
- 231100000872 sexual dysfunction Toxicity 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 229920000642 polymer Polymers 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 16
- 229910052751 metal Inorganic materials 0.000 claims description 13
- 239000002184 metal Substances 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- -1 Poly(vinyl chloride) Polymers 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 239000010936 titanium Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000004800 polyvinyl chloride Substances 0.000 claims description 7
- 239000004952 Polyamide Substances 0.000 claims description 6
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 6
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 229920002647 polyamide Polymers 0.000 claims description 6
- 229920000728 polyester Polymers 0.000 claims description 6
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 4
- 229910052732 germanium Inorganic materials 0.000 claims description 4
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims description 4
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052719 titanium Inorganic materials 0.000 claims description 4
- 229910021543 Nickel dioxide Inorganic materials 0.000 claims description 3
- 239000004743 Polypropylene Substances 0.000 claims description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 3
- 229910052681 coesite Inorganic materials 0.000 claims description 3
- 229910052593 corundum Inorganic materials 0.000 claims description 3
- 229910052906 cristobalite Inorganic materials 0.000 claims description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 229910052682 stishovite Inorganic materials 0.000 claims description 3
- 229910052905 tridymite Inorganic materials 0.000 claims description 3
- 229910001845 yogo sapphire Inorganic materials 0.000 claims description 3
- 230000001856 erectile effect Effects 0.000 abstract description 17
- 206010071289 Lower urinary tract symptoms Diseases 0.000 abstract description 16
- 230000006872 improvement Effects 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 11
- 230000002159 abnormal effect Effects 0.000 abstract description 8
- 230000004962 physiological condition Effects 0.000 abstract description 4
- 238000013459 approach Methods 0.000 abstract description 3
- 241000411851 herbal medicine Species 0.000 abstract description 3
- 231100000989 no adverse effect Toxicity 0.000 abstract description 2
- 210000003899 penis Anatomy 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 17
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- 238000010586 diagram Methods 0.000 description 14
- 208000010228 Erectile Dysfunction Diseases 0.000 description 12
- 201000001881 impotence Diseases 0.000 description 12
- 239000003381 stabilizer Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229920001609 Poly(3,4-ethylenedioxythiophene) Polymers 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 206010036596 premature ejaculation Diseases 0.000 description 6
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000001568 sexual effect Effects 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- POPACFLNWGUDSR-UHFFFAOYSA-N CO[Si](C)(C)C Chemical compound CO[Si](C)(C)C POPACFLNWGUDSR-UHFFFAOYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 210000005226 corpus cavernosum Anatomy 0.000 description 3
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000010339 dilation Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 108010078321 Guanylate Cyclase Proteins 0.000 description 2
- 102000014469 Guanylate cyclase Human genes 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000012255 powdered metal Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000035936 sexual power Effects 0.000 description 2
- 229960003310 sildenafil Drugs 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 229960000835 tadalafil Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 229960002381 vardenafil Drugs 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- 206010065584 Urethral stenosis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940117229 cialis Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940097443 levitra Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000001988 urethral stricture Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41B—SHIRTS; UNDERWEAR; BABY LINEN; HANDKERCHIEFS
- A41B17/00—Selection of special materials for underwear
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41B—SHIRTS; UNDERWEAR; BABY LINEN; HANDKERCHIEFS
- A41B9/00—Undergarments
- A41B9/02—Drawers or underpants for men, with or without inserted crotch or seat parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/41—Devices for promoting penis erection
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B3/00—Manually or mechanically operated teaching appliances working with questions and answers
- G09B3/06—Manually or mechanically operated teaching appliances working with questions and answers of the multiple-choice answer type, i.e. where a given question is provided with a series of answers and a choice has to be made
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B3/00—Manually or mechanically operated teaching appliances working with questions and answers
- G09B3/06—Manually or mechanically operated teaching appliances working with questions and answers of the multiple-choice answer type, i.e. where a given question is provided with a series of answers and a choice has to be made
- G09B3/10—Manually or mechanically operated teaching appliances working with questions and answers of the multiple-choice answer type, i.e. where a given question is provided with a series of answers and a choice has to be made wherein one set of answers is common to a plurality of questions
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41B—SHIRTS; UNDERWEAR; BABY LINEN; HANDKERCHIEFS
- A41B2400/00—Functions or special features of shirts, underwear, baby linen or handkerchiefs not provided for in other groups of this subclass
- A41B2400/32—Therapeutic use
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41B—SHIRTS; UNDERWEAR; BABY LINEN; HANDKERCHIEFS
- A41B2500/00—Materials for shirts, underwear, baby linen or handkerchiefs not provided for in other groups of this subclass
- A41B2500/20—Woven
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/063—Radiation therapy using light comprising light transmitting means, e.g. optical fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
- A61N2005/066—Radiation therapy using light characterised by the wavelength of light used infrared far infrared
Definitions
- the present invention relates to the technology field of far-infrared fibers, and more particularly to a method for treating male sexual dysfunction by using underpants comprising far-infrared fibers.
- Male sexual dysfunction includes erectile dysfunction (ED), premature ejaculation (PE), delayed ejaculation, and low libido, wherein mental factors, physiological factors and drug factors are known able to cause the male sexual dysfunction.
- mental factor may formed by melancholia, low self-confidence, and anxiety of sexual performance, and the physiological factor is commonly resulted from cardiovascular diseases, endocrine system diseases and disorders, or injury or fracture of penile corpus cavernosum.
- ED erectile dysfunction
- Phosphodiesterase-5 inhibitors are commonly used for on-demand or chronic treatment of ED.
- Viagra silicafil
- Levitra vardenafil
- Cialis tadalafil
- PDE5-I Phosphodiesterase-5 inhibitors
- U.S. Pat. No. 7,147,874 discloses a pharmaceutical composition for prevention and treatment of premature ejaculation.
- the pharmaceutical composition comprises an extract of Bufonis Venenum and an extract of Ginseng.
- 0.2 g of gel pharmaceutical composition is applied to an adult man's penis glans, such that the contraction of penile smooth muscle is reduced so as to extend erection time of the adult man.
- the pharmaceutical composition is just used to prevent men from premature ejaculation during his sexual intercourse, but fail to provide a real improvement on solving sexual dysfunction to the men.
- FIG. 1 shows a stereo diagram of the penis erection stabilizer. From FIG. 1 , it is understood that the penis erection stabilizer 1 ′ comprises a stabilizer body 11 ′ and a through-hole 12 ′ defined through a center portion of the stabilizer body 11 ′. It is well know that, the blood supplied to the spongy tissue of an adult man's penis would flow back via vein when the adult man ejaculates or loses tension due to fatigue under sexual intercourse.
- the blood in the expanded penis should first pass through a small diameter portion of the through-hole 12 ′, such that the small diameter portion keeps the blood so as to retard the discharge of the blood.
- the erected state of the penis can be maintained for a time sufficient for the completion of the sexual intercourse. It is worth noting that, owing to the fact that the use way of the penis erection stabilizer 1 ′ is to sleeve on user's penis, it is presumably that frequently-repeating use of the penis erection stabilizer 1 ′ would cause the injury of the penis.
- the present invention particularly discloses a method for treating male sexual dysfunction by using underpants comprising far-infrared fibers.
- underpants comprising far-infrared fibers.
- a variety of clinical data have proved that, after wearing this underpants for 3 months, both the men diagnosed with sexual dysfunction and the men not sure to suffer from sexual dysfunction have an apparent progress on improvements of their erectile ability, erectile quality, ejaculation control ability, and lower urinary tract symptoms (LUTS).
- clinical data have also proved that, despite the fact that a male person wears the underpants provided by the present invention for three months, there is no any adverse effect induced by the underpants so as to cause the physiological condition of the men be abnormal.
- the inventor of the present invention provides an embodiment of the method for treating male sexual dysfunction by using underpants, comprising following steps:
- the inventor of the present invention further provides another one embodiment of the method for treating male sexual dysfunction by using underpants, comprising following steps:
- the type of the underpants is selected from the group consisting of briefs, boxer briefs and boxer shorts.
- the far-infrared powders comprises powdered titanium (Ti) with a first metal weight percent of 11-18 wt %, powdered germanium (Ge) with a second metal weight percent of 0.1-0.2 wt % and powdered zinc (Zn) with a third metal weight percent of 0.05-0.15 wt %.
- the far-infrared fibers are able to emit a far-infrared ray with a wavelength in a range from 2 ⁇ m to 22 ⁇ m, and the emissivity of the far-infrared ray is above 90%.
- the far-infrared powders further comprises powdered oxide and powdered carbide for increasing the emissivity of the far-infrared ray.
- the far-infrared powders further comprises other powdered metal selected from the group consisting of powdered copper (Cu), powdered silver (Ag), powdered aluminum (Al), powdered magnesium (Mg), a mixture made by any two or more aforesaid materials.
- other powdered metal selected from the group consisting of powdered copper (Cu), powdered silver (Ag), powdered aluminum (Al), powdered magnesium (Mg), a mixture made by any two or more aforesaid materials.
- FIG. 1 shows a stereo diagram of a penis erection stabilizer
- FIG. 2A and FIG. 2B show stereo diagrams of a first embodiment of an underpants capable of improving male sexual dysfunction
- FIG. 3 shows a cross-sectional view of one far-infrared fiber
- FIG. 4A , FIG. 4B and FIG. 4C show a schematic production processing flow of the underpants capable of improving male sexual dysfunction
- FIG. 5 shows a stereo diagram of a second embodiment of the underpants capable of improving male sexual dysfunction
- FIG. 6 shows a stereo diagram of a third embodiment of the underpants capable of improving male sexual dysfunction
- FIG. 7 shows a diagram for introducing an IIEF-5 questionnaire
- FIG. 8 shows a diagram for introducing a QEQ questionnaire
- FIG. 9 shows a diagram for introducing a PEDT questionnaire
- FIG. 10 shows a diagram for introducing an IPSS questionnaire
- FIG. 11 shows a data graph of time of clinical experiment versus average score of questionnaire
- FIG. 12 shows a data graph of time of clinical experiment versus average score of questionnaire
- FIG. 13 shows a data graph for describing questionnaire score variation between adjacent two months
- FIG. 14 shows a data graph for describing questionnaire score variation between adjacent two months
- FIG. 15 shows a data graph of time of clinical experiment versus average score of questionnaire
- FIG. 16 shows a data graph of time of clinical experiment versus average score of questionnaire
- FIG. 17 shows a data graph for describing questionnaire score variation between adjacent two months
- FIG. 18 shows a data graph for describing questionnaire score variation between adjacent two months
- FIG. 19 shows a data graph of time of clinical experiment versus average score of questionnaire
- FIG. 20 shows a data graph of time of clinical experiment versus average score of questionnaire
- FIG. 21 shows a data graph for describing questionnaire score variation between adjacent two months
- FIG. 22 shows a data graph for describing questionnaire score variation between adjacent two months
- FIG. 23 shows a data graph of time of clinical experiment versus average score of questionnaire
- FIG. 24 shows a data graph of time of clinical experiment versus average score of questionnaire
- FIG. 25 shows a data graph for describing questionnaire score variation between adjacent two months.
- FIG. 26 shows a data graph for describing questionnaire score variation between adjacent two months.
- the inventors of the present invention find that the underpants comprising far-infrared fibers has a particular function to improve male sexual dysfunction.
- FIG. 2A and FIG. 2B stereo diagrams of a first embodiment of an underpants capable of improving male sexual dysfunction are provided.
- the underpants 1 capable of improving male sexual dysfunction is weaved from a plurality of far-infrared fibers 11 and a plurality of fibers 12 , wherein the far-infrared fibers 11 has a fiber amount occupying 20 - 50 percent of a total fiber amount of the underpants 1 .
- FIG. 2A and FIG. 2B indicate that the front rise portion 13 and the crotch portion 14 of the underpants 1 is constituted by the far-infrared fibers 11 , and other portions of the underpants 1 is weaved from the fibers 12 .
- FIG. 3 shows a cross-sectional view of one far-infrared fiber.
- the far-infrared fiber 11 comprises a polymer sheath 111 and far-infrared powders 112 doped in or enclosed by the polymer sheath 111 .
- the manufacturing material of the polymer sheath 111 is selected from the group consisting of polyester (PET), polyurethane (PU), Poly(vinyl chloride) (PVC), poly propylene (PP), and polyamide (PA).
- PET polyester
- PU polyurethane
- PVC Poly(vinyl chloride)
- PP poly propylene
- PA polyamide
- vinyl contains phthalate chemicals or similar plasticizers that are used to turn hard polyvinyl chloride (PVC) into soft and pliable vinyl.
- the polymer sheath 11 can also be made of a polymer compound comprising silica of at least 50 wt %, wherein the chemical structure of the polymer compound is presented by following chemical formula 1.
- n is an integer in a range from 50 to 100.
- the far-infrared powders comprises powdered titanium (Ti) with a first metal weight percent of 11-18 wt %, powdered germanium (Ge) with a second metal weight percent of 0.1-0.2 wt % and powdered zinc (Zn) with a third metal weight percent of 0.05-0.15 wt %.
- the far-infrared powders 112 further comprises powdered oxide and powdered carbide for increasing the emissivity of the far-infrared ray of the far-infrared fibers 11 , wherein the powdered oxide is selected from the group consisting of: Al 2 O 3 , MgO, NiO 2 , SiO 2 , ZrO 2 , and a mixture made by any two or more aforesaid materials. Moreover, the powdered carbide is selected from the group consisting of: TaC, ZrC, SiC, and a mixture made by any two or more aforesaid materials.
- the front rise portion 13 and the crotch portion 14 of the underpants 1 are able to emit the far-infrared ray having an emissivity greater than 90% and a wavelength of 2-22 ⁇ m.
- other powdered metal such as powdered copper (Cu), powdered silver (Ag), powdered aluminum (Al), or powdered magnesium (Mg) can also be mixed into the far-infrared powders 112 .
- FIG. 4A , FIG. 4B and FIG. 4C show a schematic production processing flow of the underpants capable of improving male sexual dysfunction.
- the underpants 1 capable of improving male sexual dysfunction is manufactured through following process flow:
- FIG. 5 illustrates a stereo diagram of a second embodiment of the underpants capable of improving male sexual dysfunction.
- the far-infrared fibers 11 is a blend fabric of the far-infrared fibers 11 and the fibers 12 , wherein the far-infrared fibers 11 has a maximum fiber amount occupying 50 percent of a total fiber amount of the underpants 1 .
- the far-infrared fibers 11 content of the underpants 1 must be limited to lower than 50% because the cost of the far-infrared fibers 11 is higher than the general fibers' 12 .
- FIG. 6 shows a stereo diagram of a third embodiment of the underpants capable of improving male sexual dysfunction. Compared FIG. 5 with FIG. 6 , it is understood that the underpants 1 shown in FIG. 6 is weaved merely from the far-infrared fibers 11 , such that the far-infrared fibers 11 content of the underpants 1 is 100%.
- a clinical trial is, essentially, any form of planned experiment that involves patients and is designed to elucidate the most effective treatment for patients with the underpants 1 weaved from the far-infrared fibers 11 and the fibers 12 . More particularly, first clinical trials are typically utilized to evaluate the effectiveness of the underpants 1 on improving sexual dysfunction of adult men. According to following Table (1), adult men diagnosed with sexual dysfunction are chosen as test subjects, and further divided into control group (abbreviated to group C) and experimental group (abbreviated to group E) for completing 3-month clinical trials. It needs to further explain that, both the adult men of the group C and the group E wear the underpants 1 provided by the present invention.
- the primary difference between the group C and the group E is that the adult men of the group C has been informed that the underpants they wore is a commercial underpants.
- physiology examination reports to be “abnormal” means the adult men suffer from hypertension.
- test subjects are requested to come back for follow up at the hospital every 1 month for completing the filling of four questionnaires of IIEF-5, QEQ, PEDT, and IPSS. Moreover, physiological data of the test subjects are also measured and recorded by nursing personnel. Diagrams of IIEF-5 questionnaire, QEQ questionnaire, PEDT questionnaire, and IPSS questionnaire are displayed in FIG. 7 , FIG. 8 , FIG. 9 , and FIG. 10 , respectively.
- FIG. 11 shows a data graph of time of clinical experiment versus average score of questionnaire
- FIG. 12 shows a data graph of time of clinical experiment versus average score of questionnaire. From the data of clinical trials provided in FIG. 11 and FIG. 12 , it is found that, compared to the adult men wearing the underpants provided by the present invention for one month, the adult men wearing the underpants provided by the present invention for three months have an apparent progress on improvements of their erectile ability and erectile quality.
- FIG. 13 shows a data graph for describing questionnaire score variation between adjacent two months
- FIG. 14 shows a data graph for describing questionnaire score variation between adjacent two months. From the data of clinical trials provided in FIG. 13 and FIG.
- the adult men wearing the underpants provided by the present invention for three months have an apparent progress on improvements of their erectile ability and erectile quality, compared to the adult men wearing the underpants provided by the present invention for one month.
- FIG. 15 shows a data graph of time of clinical experiment versus average score of questionnaire
- FIG. 16 shows a data graph of time of clinical experiment versus average score of questionnaire. From the data of clinical trials provided in FIG. 15 and FIG. 16 , it is found that, compared to the adult men wearing the underpants provided by the present invention for one month, the adult men wearing the underpants provided by the present invention for three months have an apparent progress on improvements of their ejaculation control ability and lower urinary tract symptoms (LUTS).
- FIG. 17 shows a data graph for describing questionnaire score variation between adjacent two months
- FIG. 18 shows a data graph for describing questionnaire score variation between adjacent two months. From the data of clinical trials provided in FIG. 17 and FIG.
- the adult men wearing the underpants provided by the present invention for three months have an apparent progress on improvements of their ejaculation control ability and lower urinary tract symptoms (LUTS), compared to the adult men wearing the underpants provided by the present invention for one month.
- LUTS lower urinary tract symptoms
- Second clinical trials are planned for verifying the accuracy of the data corrected from the first clinical trials.
- adult men not sure to suffer from sexual dysfunction are chosen as test subjects, and further divided into control group (abbreviated to group C) and experimental group (abbreviated to group E) for completing 3-month clinical trials.
- both the adult men of the group C and the group E wear the underpants 1 provided by the present invention.
- the primary difference between the group C and the group E is that the adult men of the group C has been informed that the underpants they wore is a commercial underpants.
- physiology examination reports to be “abnormal” means the adult men suffer from hypertension.
- FIG. 19 shows a data graph of time of clinical experiment versus average score of questionnaire
- FIG. 20 shows a data graph of time of clinical experiment versus average score of questionnaire
- FIG. 21 shows a data graph for describing questionnaire score variation between adjacent two months
- FIG. 22 shows a data graph for describing questionnaire score variation between adjacent two months. From the data of clinical trials provided in FIG. 21 and FIG. 22 , it is further understood that, the adult men wearing the underpants provided by the present invention for three months have an apparent progress on improvements of their erectile ability and erectile quality, compared to the adult men wearing the underpants provided by the present invention for one month.
- FIG. 23 shows a data graph of time of clinical experiment versus average score of questionnaire
- FIG. 24 shows a data graph of time of clinical experiment versus average score of questionnaire. From the data of clinical trials provided in FIG. 23 and FIG. 24 , it is found that, compared to the adult men wearing the underpants provided by the present invention for one month, the adult men wearing the underpants provided by the present invention for three months have an apparent progress on improvements of their ejaculation control ability and lower urinary tract symptoms (LUTS).
- FIG. 25 shows a data graph for describing questionnaire score variation between adjacent two months
- FIG. 26 shows a data graph for describing questionnaire score variation between adjacent two months. From the data of clinical trials provided in FIG. 25 and FIG.
- the adult men wearing the underpants provided by the present invention for three months have an apparent progress on improvements of their ejaculation control ability and lower urinary tract symptoms (LUTS), compared to the adult men wearing the underpants provided by the present invention for one month.
- LUTS lower urinary tract symptoms
- the far-infrared fibers 11 contained by the underpants 1 would emit electromagnetic radiation in the far infrared region (wavelength 4-14 microns).
- Such far-infrared rays have been examined for effects on human leukocyte activity and on lipid peroxidation of unsaturated fatty acids.
- related research also report that far-infrared rays significantly increase intracellular calcium ion concentration, phagocytosis, and generation of reactive oxygen species in neutrophils, and the blastogenetic response of lymphocytes to mitogens.
- far-infrared rays Despite the increase in reactive oxygen species generated by neutrophils, lipid peroxidation from unsaturated fatty acid may be markedly inhibited by far-infrared rays, related research suggest that the far-infrared rays can be widely used for cosmetic, therapeutic, and preservative purposes, appear capable of potentiating leukocyte functions without promoting oxidative injury.
- far-infrared ray (FIR) radiation has been proved to be beneficial to human health.
- related research have investigated the effect carried out by FIR on the expression of calmodulin (Cam) protein and nitric oxide (NO) production in human body.
- NO nitric oxide
- cGMP cyclic guanosine monophosphate
- Nitric oxide diffuses to smooth muscle cells and activates guanylyl cyclase.
- cGMP activates a cGMP-dependent protein kinase which phosphorylates myosin light chain and causes vascular relaxation.
- the method for treating male sexual dysfunction by using underpants comprising far-infrared fibers proposed by the present invention have been introduced completely and clearly; in summary, the present invention includes the advantages of:
- the present invention particularly discloses a method for treating male sexual dysfunction by using underpants comprising far-infrared fibers.
- underpants comprising far-infrared fibers.
Abstract
Differing from conventional approaches for improving sexual dysfunction of an adult man being commonly carried out by letting the adult man administer a dosage of synthetic drug or a composition of Chinese herbal medicines, the present invention particularly discloses a method for treating male sexual dysfunction by using underpants comprising far-infrared fibers. A variety of clinical data have proved that, after wearing this underpants for 3 months, both the men diagnosed with sexual dysfunction and the men not sure to suffer from sexual dysfunction have an apparent progress on improvements of their erectile ability, erectile quality, ejaculation control ability, and lower urinary tract symptoms (LUTS). Moreover, clinical data have also proved that, despite the fact that a male person wears the underpants provided by the present invention for three months, there is no adverse effect induced by the underpants for causing the physiological condition of the men be abnormal.
Description
- The present invention relates to the technology field of far-infrared fibers, and more particularly to a method for treating male sexual dysfunction by using underpants comprising far-infrared fibers.
- Male sexual dysfunction includes erectile dysfunction (ED), premature ejaculation (PE), delayed ejaculation, and low libido, wherein mental factors, physiological factors and drug factors are known able to cause the male sexual dysfunction. Moreover, clinical research reports that mental factor may formed by melancholia, low self-confidence, and anxiety of sexual performance, and the physiological factor is commonly resulted from cardiovascular diseases, endocrine system diseases and disorders, or injury or fracture of penile corpus cavernosum.
- Statistical data indicate that, about half of all men between the ages of 40 and 70 suffer from erectile dysfunction (ED) to some degree. ED is one of the most common chronic diseases affecting men and its prevalence increases with aging.
- Phosphodiesterase-5 inhibitors (PDE5-I) are commonly used for on-demand or chronic treatment of ED. Viagra (sildenafil), Levitra (vardenafil) and Cialis (tadalafil) are currently known prescription ED drugs comprising PDE5-I. By dilating blood vessels and relaxing smooth muscle tissues in penis, these drugs successfully improve or treat erectile dysfunction. However, this is the result of a series of conditions occurring simultaneously. When ED drug is taken correctly, it is no longer a concern. Nevertheless, in the mind of the public, use of the ED drug is at this time invariably considered dangerous for patients with heart disease. Moreover, it is well known that these ED drugs may cause unwanted side effects that require medical attention.
- In view of the fact that most of ED drugs induce unwanted side effects, U.S. Pat. No. 7,147,874 discloses a pharmaceutical composition for prevention and treatment of premature ejaculation. The pharmaceutical composition comprises an extract of Bufonis Venenum and an extract of Ginseng. To carry out treatment of premature ejaculation, 0.2 g of gel pharmaceutical composition is applied to an adult man's penis glans, such that the contraction of penile smooth muscle is reduced so as to extend erection time of the adult man. However, the pharmaceutical composition is just used to prevent men from premature ejaculation during his sexual intercourse, but fail to provide a real improvement on solving sexual dysfunction to the men.
- Accordingly, U.S. Pat. No. 8,211,006 discloses a penis erection stabilizer.
FIG. 1 shows a stereo diagram of the penis erection stabilizer. FromFIG. 1 , it is understood that thepenis erection stabilizer 1′ comprises astabilizer body 11′ and a through-hole 12′ defined through a center portion of thestabilizer body 11′. It is well know that, the blood supplied to the spongy tissue of an adult man's penis would flow back via vein when the adult man ejaculates or loses tension due to fatigue under sexual intercourse. In the meantime, because the adult man's penis is sleeved with thepenis erection stabilizer 1′, the blood in the expanded penis should first pass through a small diameter portion of the through-hole 12′, such that the small diameter portion keeps the blood so as to retard the discharge of the blood. Eventually, the erected state of the penis can be maintained for a time sufficient for the completion of the sexual intercourse. It is worth noting that, owing to the fact that the use way of thepenis erection stabilizer 1′ is to sleeve on user's penis, it is presumably that frequently-repeating use of thepenis erection stabilizer 1′ would cause the injury of the penis. - From above descriptions, it is clear that both the pharmaceutical composition for prevention of premature ejaculation and the
penis erection stabilizer 1′ show practical-application drawbacks. In view of that, inventors of the present application have made great efforts to make inventive research thereon and eventually provided a method for treating male sexual dysfunction by using underpants comprising far-infrared fibers. - Differing from the fact that conventional approaches for improving sexual dysfunction of an adult man are commonly carried out by letting the adult man administer a dosage of synthetic drug or a composition of Chinese herbal medicines, the present invention particularly discloses a method for treating male sexual dysfunction by using underpants comprising far-infrared fibers. A variety of clinical data have proved that, after wearing this underpants for 3 months, both the men diagnosed with sexual dysfunction and the men not sure to suffer from sexual dysfunction have an apparent progress on improvements of their erectile ability, erectile quality, ejaculation control ability, and lower urinary tract symptoms (LUTS). Moreover, clinical data have also proved that, despite the fact that a male person wears the underpants provided by the present invention for three months, there is no any adverse effect induced by the underpants so as to cause the physiological condition of the men be abnormal.
- In order to achieve the primary objective of the present invention, the inventor of the present invention provides an embodiment of the method for treating male sexual dysfunction by using underpants, comprising following steps:
-
- (1) providing an underpants weaved from a plurality of far-infrared fibers and a plurality of fibers, wherein each of the far-infrared fibers comprises a polymer sheath and far-infrared metal powders doped in or enclosed by the polymer sheath; moreover, the far-infrared fibers having a fiber amount occupying 40-60 percent of a total fiber amount of the underpants; and
- (2) letting adult men diagnosed with sexual dysfunction or not sure to suffer from sexual dysfunction wear the underpants for at least one month.
- Moreover, for achieving the primary objective of the present invention, the inventor of the present invention further provides another one embodiment of the method for treating male sexual dysfunction by using underpants, comprising following steps:
-
- (1) providing an underpants weaved from a plurality of far-infrared fibers, wherein each of the far-infrared fibers comprises a polymer sheath and far-infrared powders doped in or enclosed by the polymer sheath; and
- (2) letting adult men diagnosed with sexual dysfunction or not sure to suffer from sexual dysfunction wear the underpants for at least one month.
- In the two embodiments of the method, wherein the type of the underpants is selected from the group consisting of briefs, boxer briefs and boxer shorts.
- In the two embodiments of the method, wherein the far-infrared powders comprises powdered titanium (Ti) with a first metal weight percent of 11-18 wt %, powdered germanium (Ge) with a second metal weight percent of 0.1-0.2 wt % and powdered zinc (Zn) with a third metal weight percent of 0.05-0.15 wt %.
- In the two embodiments of the method, wherein the far-infrared fibers are able to emit a far-infrared ray with a wavelength in a range from 2 μm to 22 μm, and the emissivity of the far-infrared ray is above 90%.
- In the two embodiments of the method, wherein the far-infrared powders further comprises powdered oxide and powdered carbide for increasing the emissivity of the far-infrared ray.
- In the two embodiments of the method, wherein the far-infrared powders further comprises other powdered metal selected from the group consisting of powdered copper (Cu), powdered silver (Ag), powdered aluminum (Al), powdered magnesium (Mg), a mixture made by any two or more aforesaid materials.
- The invention as well as a preferred mode of use and advantages thereof will be best understood by referring to the following detailed description of an illustrative embodiment in conjunction with the accompanying drawings, wherein:
-
FIG. 1 shows a stereo diagram of a penis erection stabilizer; -
FIG. 2A andFIG. 2B show stereo diagrams of a first embodiment of an underpants capable of improving male sexual dysfunction; -
FIG. 3 shows a cross-sectional view of one far-infrared fiber; -
FIG. 4A ,FIG. 4B andFIG. 4C show a schematic production processing flow of the underpants capable of improving male sexual dysfunction; -
FIG. 5 shows a stereo diagram of a second embodiment of the underpants capable of improving male sexual dysfunction; -
FIG. 6 shows a stereo diagram of a third embodiment of the underpants capable of improving male sexual dysfunction; -
FIG. 7 shows a diagram for introducing an IIEF-5 questionnaire; -
FIG. 8 shows a diagram for introducing a QEQ questionnaire; -
FIG. 9 shows a diagram for introducing a PEDT questionnaire; -
FIG. 10 shows a diagram for introducing an IPSS questionnaire; -
FIG. 11 shows a data graph of time of clinical experiment versus average score of questionnaire; -
FIG. 12 shows a data graph of time of clinical experiment versus average score of questionnaire; -
FIG. 13 shows a data graph for describing questionnaire score variation between adjacent two months; -
FIG. 14 shows a data graph for describing questionnaire score variation between adjacent two months; -
FIG. 15 shows a data graph of time of clinical experiment versus average score of questionnaire; -
FIG. 16 shows a data graph of time of clinical experiment versus average score of questionnaire; -
FIG. 17 shows a data graph for describing questionnaire score variation between adjacent two months; -
FIG. 18 shows a data graph for describing questionnaire score variation between adjacent two months; -
FIG. 19 shows a data graph of time of clinical experiment versus average score of questionnaire; -
FIG. 20 shows a data graph of time of clinical experiment versus average score of questionnaire; -
FIG. 21 shows a data graph for describing questionnaire score variation between adjacent two months; -
FIG. 22 shows a data graph for describing questionnaire score variation between adjacent two months; -
FIG. 23 shows a data graph of time of clinical experiment versus average score of questionnaire; -
FIG. 24 shows a data graph of time of clinical experiment versus average score of questionnaire; -
FIG. 25 shows a data graph for describing questionnaire score variation between adjacent two months; and -
FIG. 26 shows a data graph for describing questionnaire score variation between adjacent two months. - To more clearly describe a method for treating male sexual dysfunction by using underpants comprising far-infrared fibers according to the present invention, embodiments of the present invention will be described in detail with reference to the attached drawings hereinafter.
- The inventors of the present invention find that the underpants comprising far-infrared fibers has a particular function to improve male sexual dysfunction. Please refer to
FIG. 2A andFIG. 2B , where stereo diagrams of a first embodiment of an underpants capable of improving male sexual dysfunction are provided. According toFIG. 2A andFIG. 2B , it is understood that theunderpants 1 capable of improving male sexual dysfunction is weaved from a plurality of far-infrared fibers 11 and a plurality offibers 12, wherein the far-infrared fibers 11 has a fiber amount occupying 20-50 percent of a total fiber amount of theunderpants 1. For instance,FIG. 2A andFIG. 2B indicate that thefront rise portion 13 and thecrotch portion 14 of theunderpants 1 is constituted by the far-infrared fibers 11, and other portions of theunderpants 1 is weaved from thefibers 12. -
FIG. 3 shows a cross-sectional view of one far-infrared fiber. In the present invention, the far-infrared fiber 11 comprises apolymer sheath 111 and far-infrared powders 112 doped in or enclosed by thepolymer sheath 111. Moreover, the manufacturing material of thepolymer sheath 111 is selected from the group consisting of polyester (PET), polyurethane (PU), Poly(vinyl chloride) (PVC), poly propylene (PP), and polyamide (PA). It is worth explaining that, vinyl contains phthalate chemicals or similar plasticizers that are used to turn hard polyvinyl chloride (PVC) into soft and pliable vinyl. Related research reports that phthalates are animal carcinogens and can cause fetal death, malformations, and reproductive toxicity in laboratory animals. Based on the reasons, thepolymer sheath 11 can also be made of a polymer compound comprising silica of at least 50 wt %, wherein the chemical structure of the polymer compound is presented by followingchemical formula 1. - In
chemical formula 1, n is an integer in a range from 50 to 100. On the other hand, the far-infrared powders comprises powdered titanium (Ti) with a first metal weight percent of 11-18 wt %, powdered germanium (Ge) with a second metal weight percent of 0.1-0.2 wt % and powdered zinc (Zn) with a third metal weight percent of 0.05-0.15 wt %. By such arrangement, when an adult man wear thisunderpants 1, the far-infrared ray emitted from thefront rise portion 13 and thecrotch portion 14 of theunderpants 1 would make the dilation of penile arteries of the adult man, and simultaneously urge blood to flow into the penile arteries so as to make the erection of the adult man's penis. - It needs further explain that, the far-
infrared powders 112 further comprises powdered oxide and powdered carbide for increasing the emissivity of the far-infrared ray of the far-infrared fibers 11, wherein the powdered oxide is selected from the group consisting of: Al2O3, MgO, NiO2, SiO2, ZrO2, and a mixture made by any two or more aforesaid materials. Moreover, the powdered carbide is selected from the group consisting of: TaC, ZrC, SiC, and a mixture made by any two or more aforesaid materials. By such arrangement, thefront rise portion 13 and thecrotch portion 14 of theunderpants 1 are able to emit the far-infrared ray having an emissivity greater than 90% and a wavelength of 2-22 μm. In addition, other powdered metal such as powdered copper (Cu), powdered silver (Ag), powdered aluminum (Al), or powdered magnesium (Mg) can also be mixed into the far-infrared powders 112. -
FIG. 4A ,FIG. 4B andFIG. 4C show a schematic production processing flow of the underpants capable of improving male sexual dysfunction. Theunderpants 1 capable of improving male sexual dysfunction is manufactured through following process flow: -
- step (1): as
FIG. 4A shows, to add far-infrared powders 112 into apolymer solution 111 a, and then convert thepolymer solution 111 a to a plurality ofmasterbatches 2 through polymerization and granulation process; - step (2): as
FIG. 4B shows, executing a spinning process for drawing themasterbatches 2 to a plurality of far-infrared fibers 11; and - step (3): as
FIG. 4C shows, theunderpants 1 capable of improving male sexual dysfunction is weaved from the far-infrared fibers 11 and a plurality offibers 12.
- step (1): as
- It needs to emphasize that, in spite of the fact that the fiber content of the far-
infrared fibers 11 of theunderpants 1 is in a range from 20% to 50%, that does not used for limiting the constitution of theunderpants 1. In the first embodiment, what is weaved from the far-infrared fibers 11 are only thefront rise portion 13 and thecrotch portion 14 of theunderpants 1, with the purpose of cost saving. Please refer toFIG. 5 , which illustrates a stereo diagram of a second embodiment of the underpants capable of improving male sexual dysfunction. After comparingFIG. 2B withFIG. 5 , it is found that theunderpants 1 shown inFIG. 5 is a blend fabric of the far-infrared fibers 11 and thefibers 12, wherein the far-infrared fibers 11 has a maximum fiber amount occupying 50 percent of a total fiber amount of theunderpants 1. However, for business benefit consideration, the far-infrared fibers 11 content of theunderpants 1 must be limited to lower than 50% because the cost of the far-infrared fibers 11 is higher than the general fibers' 12. - Of course, the far-
infrared fibers 11 content of theunderpants 1 may be greater than 50% without the consideration of business benefit.FIG. 6 shows a stereo diagram of a third embodiment of the underpants capable of improving male sexual dysfunction. ComparedFIG. 5 withFIG. 6 , it is understood that theunderpants 1 shown inFIG. 6 is weaved merely from the far-infrared fibers 11, such that the far-infrared fibers 11 content of theunderpants 1 is 100%. - First Clinical Trials
- A clinical trial is, essentially, any form of planned experiment that involves patients and is designed to elucidate the most effective treatment for patients with the
underpants 1 weaved from the far-infrared fibers 11 and thefibers 12. More particularly, first clinical trials are typically utilized to evaluate the effectiveness of theunderpants 1 on improving sexual dysfunction of adult men. According to following Table (1), adult men diagnosed with sexual dysfunction are chosen as test subjects, and further divided into control group (abbreviated to group C) and experimental group (abbreviated to group E) for completing 3-month clinical trials. It needs to further explain that, both the adult men of the group C and the group E wear theunderpants 1 provided by the present invention. Moreover, the primary difference between the group C and the group E is that the adult men of the group C has been informed that the underpants they wore is a commercial underpants. On the other hand, in Table (1), physiology examination reports to be “abnormal” means the adult men suffer from hypertension. -
TABLE (1) Physiology Age BMI examination Standard Over Normal Abnormal Average ± deviation Normal weight Obese Group C 3 1 49 ± 8.18 2 2 0 (n = 4) Group E 4 1 47 ± 6.45 2 3 0 (n = 5) - What is needed to emphasize is that the adult men are chosen as the test subjects after passing the following exclusion criteria:
-
- (1) ever using sex hormone agents or PDE-5 inhibitors like Sildenafil, Vardenafil, or Tadalafil administered in the 7 days previously for the treatment of male sexual dysfunction;
- (2) a long user of antihypertensive drugs, antidepressants, sedatives, anti-androgens, or medicines for treating peptic ulcer;
- (3) ever being subject to serious injuries of central system, for example, stroke or spinal cord injury;
- (4) ever suffering from erectile disorder caused by non-vascular diseases factors, such as nervous factors or hormone factors;
- (5) being an HIV patient or the patient with liver disease;
- (6) diagnosis of urethral stricture, urinary tract infection, prostatitis, prostate cancer, or bladder cancer;
- (7) sexual partner is pregnant or in a breast-feeding period;
- (8) being a patient with Peyronie's disease;
- (9) suffering from alcoholism or tobacco addiction;
- (10) suffering from cancer of prostate gland or other malignant neoplasms;
- (11) will have an operation (surgical treatment) during clinical trials period;
- (12) having an unhealthy mental status which will affect evaluations of clinical trials;
- (13) ever completing at least one sexual performance test which will affect evaluations of clinical trials; and
- (14) being ineligibility for the current study judged by investigators.
- During 3-month clinical trials, the test subjects are requested to come back for follow up at the hospital every 1 month for completing the filling of four questionnaires of IIEF-5, QEQ, PEDT, and IPSS. Moreover, physiological data of the test subjects are also measured and recorded by nursing personnel. Diagrams of IIEF-5 questionnaire, QEQ questionnaire, PEDT questionnaire, and IPSS questionnaire are displayed in
FIG. 7 ,FIG. 8 ,FIG. 9 , andFIG. 10 , respectively. - Moreover,
FIG. 11 shows a data graph of time of clinical experiment versus average score of questionnaire, andFIG. 12 shows a data graph of time of clinical experiment versus average score of questionnaire. From the data of clinical trials provided inFIG. 11 andFIG. 12 , it is found that, compared to the adult men wearing the underpants provided by the present invention for one month, the adult men wearing the underpants provided by the present invention for three months have an apparent progress on improvements of their erectile ability and erectile quality. On the other hand,FIG. 13 shows a data graph for describing questionnaire score variation between adjacent two months andFIG. 14 shows a data graph for describing questionnaire score variation between adjacent two months. From the data of clinical trials provided inFIG. 13 andFIG. 14 , it is further understood that, the adult men wearing the underpants provided by the present invention for three months have an apparent progress on improvements of their erectile ability and erectile quality, compared to the adult men wearing the underpants provided by the present invention for one month. - In addition,
FIG. 15 shows a data graph of time of clinical experiment versus average score of questionnaire, andFIG. 16 shows a data graph of time of clinical experiment versus average score of questionnaire. From the data of clinical trials provided inFIG. 15 andFIG. 16 , it is found that, compared to the adult men wearing the underpants provided by the present invention for one month, the adult men wearing the underpants provided by the present invention for three months have an apparent progress on improvements of their ejaculation control ability and lower urinary tract symptoms (LUTS). On the other hand,FIG. 17 shows a data graph for describing questionnaire score variation between adjacent two months andFIG. 18 shows a data graph for describing questionnaire score variation between adjacent two months. From the data of clinical trials provided inFIG. 17 andFIG. 18 , it is further understood that, the adult men wearing the underpants provided by the present invention for three months have an apparent progress on improvements of their ejaculation control ability and lower urinary tract symptoms (LUTS), compared to the adult men wearing the underpants provided by the present invention for one month. - Second Clinical Trials
- Second clinical trials are planned for verifying the accuracy of the data corrected from the first clinical trials. According to following Table (2), adult men not sure to suffer from sexual dysfunction are chosen as test subjects, and further divided into control group (abbreviated to group C) and experimental group (abbreviated to group E) for completing 3-month clinical trials. It needs to further explain that, both the adult men of the group C and the group E wear the
underpants 1 provided by the present invention. Moreover, the primary difference between the group C and the group E is that the adult men of the group C has been informed that the underpants they wore is a commercial underpants. On the other hand, in Table (2), physiology examination reports to be “abnormal” means the adult men suffer from hypertension. -
TABLE (2) Physiology Age BMI examination Standard Over Normal Abnormal Avg. ± deviation Normal weight Obese Group C 4 1 46.66 ± 5.36 2 3 0 (n = 5) Group E 13 1 48.93 ± 7.45 2 8 4 (n = 14) - During 3-month clinical trials, the test subjects are requested to come back for follow up at the hospital every 1 month for completing the filling of four questionnaires of IIEF-5, QEQ, PEDT, and IPSS. Moreover, physiological data of the test subjects are also measured and recorded by nursing personnel. Diagrams of IIEF-5 questionnaire, QEQ questionnaire, PEDT questionnaire, and IPSS questionnaire are displayed in
FIG. 19 ,FIG. 20 ,FIG. 21 , andFIG. 22 , respectively.FIG. 19 shows a data graph of time of clinical experiment versus average score of questionnaire, andFIG. 20 shows a data graph of time of clinical experiment versus average score of questionnaire. From the data of clinical trials provided inFIG. 19 andFIG. 20 , it is found that, compared to the adult men wearing the underpants provided by the present invention for one month, the adult men wearing the underpants provided by the present invention for three months have an apparent progress on improvements of their erectile ability and erectile quality. On the other hand,FIG. 21 shows a data graph for describing questionnaire score variation between adjacent two months andFIG. 22 shows a data graph for describing questionnaire score variation between adjacent two months. From the data of clinical trials provided inFIG. 21 andFIG. 22 , it is further understood that, the adult men wearing the underpants provided by the present invention for three months have an apparent progress on improvements of their erectile ability and erectile quality, compared to the adult men wearing the underpants provided by the present invention for one month. - In addition,
FIG. 23 shows a data graph of time of clinical experiment versus average score of questionnaire, andFIG. 24 shows a data graph of time of clinical experiment versus average score of questionnaire. From the data of clinical trials provided inFIG. 23 andFIG. 24 , it is found that, compared to the adult men wearing the underpants provided by the present invention for one month, the adult men wearing the underpants provided by the present invention for three months have an apparent progress on improvements of their ejaculation control ability and lower urinary tract symptoms (LUTS). On the other hand,FIG. 25 shows a data graph for describing questionnaire score variation between adjacent two months andFIG. 26 shows a data graph for describing questionnaire score variation between adjacent two months. From the data of clinical trials provided inFIG. 25 andFIG. 26 , it is further understood that, the adult men wearing the underpants provided by the present invention for three months have an apparent progress on improvements of their ejaculation control ability and lower urinary tract symptoms (LUTS), compared to the adult men wearing the underpants provided by the present invention for one month. - Furthermore, data of
FIG. 11 -FIG. 26 are integrated in following Table (3) and Table (4). -
TABLE (3) First month Third month Avg. Avg. Improvement status Group C of Standard of Standard P Questionnaire score ± deviation score ± deviation unimproved unimproved value IIEF-5 17.7 ± 8.53 17.33 ± 8.51 ✓ 0.92 QEQ 19.30 ± 8.46 18.11 ± 8.34 ✓ 0.76 PEDT 6.3 ± 5.21 4.44 ± 3.71 ✓ 0.38 IPSS 8.00 ± 10.72 6.00 ± 8.00 ✓ 0.64 -
TABLE (4) First month Third month Avg. Avg. Improvement status Group C of Standard of Standard P Questionnaire score ± deviation score ± deviation unimproved unimproved value IIEF-5 18.33 ± 6.54 20 ± 5.69 ✓ 0.33 26 QEQ 19.57 ± 7.53 22.53 ± 8.02 ✓ 0.24 PEDT 5.14 ± 4.22 3.16 ± 3.76 ✓ 0.12 IPSS 3.86 ± 6.40 2.58 ± 4.06 ✓ 0.45 - Therefore, data of clinical trials have proved that, after wearing the underpants provided by the present invention for three months, both the men diagnosed with sexual dysfunction and the men not sure to suffer from sexual dysfunction have an apparent progress on improvements of their erectile ability, erectile quality, ejaculation control ability, and lower urinary tract symptoms (LUTS).
- It is worth explaining that, the far-
infrared fibers 11 contained by the underpants 1 (asFIG. 5 shows) would emit electromagnetic radiation in the far infrared region (wavelength 4-14 microns). Such far-infrared rays have been examined for effects on human leukocyte activity and on lipid peroxidation of unsaturated fatty acids. Moreover, related research also report that far-infrared rays significantly increase intracellular calcium ion concentration, phagocytosis, and generation of reactive oxygen species in neutrophils, and the blastogenetic response of lymphocytes to mitogens. Despite the increase in reactive oxygen species generated by neutrophils, lipid peroxidation from unsaturated fatty acid may be markedly inhibited by far-infrared rays, related research suggest that the far-infrared rays can be widely used for cosmetic, therapeutic, and preservative purposes, appear capable of potentiating leukocyte functions without promoting oxidative injury. On the other hand, far-infrared ray (FIR) radiation has been proved to be beneficial to human health. Particularly, related research have investigated the effect carried out by FIR on the expression of calmodulin (Cam) protein and nitric oxide (NO) production in human body. Experimental data indicated a significant increase in Cam protein in FIR-treated RAW 264.7 macrophages with or without the addition of lipopolysaccharide (LPS). In addition, the amount of NO was slightly higher but increased significantly in FIR plus LPS-treated RAW 264.7 macrophages. - It is worth explaining that, the physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. Related research indicates that NO would activate the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), so as to produce smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. NO in vascular regulation couples endothelial and smooth muscle cells. In blood vessels, vascular dilation is initiated by acetylcholine acting at muscarinic receptors on endothelial cells. This initiates IP3 production, Ca2+ release from endoplasmic reticulum and activation of NO synthase by Ca2+/calmodulin. Nitric oxide diffuses to smooth muscle cells and activates guanylyl cyclase. cGMP activates a cGMP-dependent protein kinase which phosphorylates myosin light chain and causes vascular relaxation.
- It is repeated that, when an adult man wear this underpants 1 (as shown in
FIG. 5 ), the far-infrared rays emitted from thefront rise portion 13 and thecrotch portion 14 of theunderpants 1 would make the dilation of penile arteries of the adult man, and simultaneously urge blood to flow into the penile arteries so as to make the erection of the adult man's penis. Accordingly, physiological data of the test subjects measured by nursing personnel are integrated in following Table (5), Table (6) and Table (7). Therefore, the recorded physiological data have proved that, despite the fact that the adult men wear the underpants provided by the present invention for three months, there is no any adverse effect induced by the underpants so as to cause the physiological condition of the men be abnormal. -
TABLE 5 First month Standard physiological data Average ± deviation Maximum Minimum SBP (mmHg) 126.64 ± 9.92 147.00 108.00 DBP (mmHg) 80.86 ± 9.13 98.00 64.00 Body Temp. (° C.) 36.37 ± 0.56 37.2 35.00 Pulse (bit/min) 73.29 ± 7.25 93.00 64.00 -
TABLE 6 Second month Standard physiological data Average ± deviation Maximum Minimum SBP (mmHg) 123.33 ± 8.50 140.00 110.00 DBP (mmHg) 83.44 ± 6.64 92.00 71.00 Body Temp. (° C.) 36.64 ± 0.29 37.00 36.20 Pulse (bit/min) 74.44 ± 8.23 96.00 64.00 -
TABLE 7 Third month Standard physiological data Average ± deviation Maximum Minimum SBP (mmHg) 126.00 ± 8.29 135.00 115.00 DBP (mmHg) 84.00 ± 7.79 93.00 74.00 Body Temp. (° C.) 36.20 ± 0.28 36.60 36.00 Pulse (bit/min) 73.67 ± 12.12 90.00 61.00 - Therefore, through above descriptions, the method for treating male sexual dysfunction by using underpants comprising far-infrared fibers proposed by the present invention have been introduced completely and clearly; in summary, the present invention includes the advantages of:
- (1) Differing from conventional approaches for improving sexual dysfunction of an adult man being commonly carried out by letting the adult man administer a dosage of synthetic drug or a composition of Chinese herbal medicines, the present invention particularly discloses a method for treating male sexual dysfunction by using underpants comprising far-infrared fibers. A variety of clinical data have proved that, after wearing this underpants for three months, both the men diagnosed with sexual dysfunction and the men not sure to suffer from sexual dysfunction have an apparent progress on improvements of their erectile ability, erectile quality, ejaculation control ability, and lower urinary tract symptoms (LUTS).
- (2) Moreover, clinical data have also proved that, despite the fact that a male person wears the underpants provided by the present invention for three months, there is no adverse effect induced by the underpants for causing the physiological condition of the men be abnormal.
- The above description is made on embodiments of the present invention. However, the embodiments are not intended to limit scope of the present invention, and all equivalent implementations or alterations within the spirit of the present invention still fall within the scope of the present invention.
Claims (18)
1. A method for treating male sexual dysfunction by using underpants comprising far-infrared fibers, comprising following steps:
(1) providing an underpants weaved from a plurality of far-infrared fibers and a plurality of fibers, wherein each of the far-infrared fibers comprises a polymer sheath and far-infrared powders doped in or enclosed by the polymer sheath; moreover, the far-infrared fibers having a fiber amount occupying 20-50 percent of a total fiber amount of the underpants; and
(2) letting adult men diagnosed with sexual dysfunction or not sure to suffer from sexual dysfunction wear the underpants for at least one month.
2. The method of claim 1 , wherein the type of the underpants is selected from the group consisting of briefs, boxer briefs and boxer shorts.
3. The method of claim 1 , wherein the manufacturing material of the polymer sheath is selected from the group consisting of polyester (PET), polyurethane (PU), Poly(vinyl chloride) (PVC), poly propylene (PP), and polyamide (PA).
5. The method of claim 1 , wherein the far-infrared powders comprises powdered titanium (Ti) with a first metal weight percent of 11-18 wt %, powdered germanium (Ge) with a second metal weight percent of 0.1-0.2 wt % and powdered zinc (Zn) with a third metal weight percent of 0.05-0.15 wt %.
6. The method of claim 5 , wherein the far-infrared fibers are able to emit a far-infrared ray with a wavelength in a range from 2 μm to 22 μm, and the emissivity of the far-infrared ray is above 90%.
7. The method of claim 1 , wherein the far-infrared powders further comprises powdered oxide and powdered carbide for increasing the emissivity of the far-infrared ray.
8. The method of claim 7 , wherein the powdered oxide is selected from the group consisting of: Al2O3, MgO, NiO2, SiO2, ZrO2, and a mixture made by any two or more aforesaid materials.
9. The method of claim 7 , wherein the powdered carbide is selected from the group consisting of: TaC, ZrC, SiC, and a mixture made by any two or more aforesaid materials.
10. A method for treating male sexual dysfunction by using underpants comprising far-infrared fibers, comprising following steps:
(1) providing an underpants weaved from a plurality of far-infrared fibers, wherein each of the far-infrared fibers comprises a polymer sheath and far-infrared powders doped in or enclosed by the polymer sheath; and
(2) letting adult men diagnosed with sexual dysfunction or not sure to suffer from sexual dysfunction wear the underpants for at least one month.
11. The method of claim 10 , wherein the type of the underpants is selected from the group consisting of briefs, boxer briefs and boxer shorts.
12. The method of claim 10 , wherein the manufacturing material of the polymer sheath is selected from the group consisting of polyester (PET), polyurethane (PU), Poly(vinyl chloride) (PVC), poly propylene (PP), and polyamide (PA).
14. The method of claim 10 , wherein the far-infrared powders comprises powdered titanium (Ti) with a first metal weight percent of 11-18 wt %, powdered germanium (Ge) with a second metal weight percent of 0.1-0.2 wt % and powdered zinc (Zn) with a third metal weight percent of 0.05-0.15 wt %.
15. The method of claim 14 , wherein the far-infrared fibers are able to emit a far-infrared ray with a wavelength in a range from 2 μm to 22 μm, and the emissivity of the far-infrared ray is above 90%.
16. The method of claim 14 , wherein the far-infrared powders further comprises powdered oxide and powdered carbide for increasing the emissivity of the far-infrared ray.
17. The method of claim 16 , wherein the powdered oxide is selected from the group consisting of: Al2O3, MgO, NiO2, SiO2, ZrO2, and a mixture made by any two or more aforesaid materials.
18. The method of claim 16 , wherein the powdered carbide is selected from the group consisting of: TaC, ZrC, SiC, and a mixture made by any two or more aforesaid materials.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/709,516 US20190083807A1 (en) | 2017-09-20 | 2017-09-20 | Method for treating male sexual dysfunction by using underpants comprising far-infrared fibers |
US16/562,349 US11000695B2 (en) | 2017-09-20 | 2019-09-05 | Method for treating male sexual dysfunction by using underpants comprising far-infrared fibers |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/709,516 US20190083807A1 (en) | 2017-09-20 | 2017-09-20 | Method for treating male sexual dysfunction by using underpants comprising far-infrared fibers |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/562,349 Continuation US11000695B2 (en) | 2017-09-20 | 2019-09-05 | Method for treating male sexual dysfunction by using underpants comprising far-infrared fibers |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190083807A1 true US20190083807A1 (en) | 2019-03-21 |
Family
ID=65719724
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/709,516 Abandoned US20190083807A1 (en) | 2017-09-20 | 2017-09-20 | Method for treating male sexual dysfunction by using underpants comprising far-infrared fibers |
US16/562,349 Active US11000695B2 (en) | 2017-09-20 | 2019-09-05 | Method for treating male sexual dysfunction by using underpants comprising far-infrared fibers |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/562,349 Active US11000695B2 (en) | 2017-09-20 | 2019-09-05 | Method for treating male sexual dysfunction by using underpants comprising far-infrared fibers |
Country Status (1)
Country | Link |
---|---|
US (2) | US20190083807A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111109963B (en) * | 2018-10-30 | 2021-09-24 | 绿能奈米科技有限公司 | Bedding structure with non-power energy layer and far infrared fiber |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0473226A (en) * | 1989-07-25 | 1992-03-09 | J Pii U:Kk | Yarn for woven fabric containing far infrared radiation substance and production thereof |
US20040225049A1 (en) * | 2000-05-19 | 2004-11-11 | Toshio Komuro | Composition for far infrared irradiation with excellent antistatic property and fiber and textile product both containing the same |
US20130117911A1 (en) * | 2010-07-22 | 2013-05-16 | Robert Bosch Gmbh | Functional underpants for men |
US9408483B2 (en) * | 2012-06-22 | 2016-08-09 | Green Energy Nano Technology Co., Ltd. | Manufacturing method for non-powered energy layer |
US20160353818A1 (en) * | 2015-04-06 | 2016-12-08 | George Psipsikas | Next to skin garments manufactured from a fabric coated with a composite material based on metal oxides and ainorganic material |
US20170135427A1 (en) * | 2015-11-13 | 2017-05-18 | Ap Trennel Limited | Functional fabric and manufacturing method thereof |
US20180127903A1 (en) * | 2006-03-29 | 2018-05-10 | Chapman Thermal Products, Inc. | Breathable Fire Resistant Fabrics |
US20180305520A1 (en) * | 2017-04-19 | 2018-10-25 | Joy In Biotechnology Co., Ltd. | High content far-infrared elastomer and method of manufacturing the same |
US20190009105A1 (en) * | 2016-03-09 | 2019-01-10 | Johnson & Johnson Consumer Inc. | Far infrared radiation heat patch |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6464245B1 (en) * | 2017-09-20 | 2019-02-06 | ▲緑▼能奈米科技有限公司 | Underwear to enhance the masculine function of far-infrared fibers |
-
2017
- 2017-09-20 US US15/709,516 patent/US20190083807A1/en not_active Abandoned
-
2019
- 2019-09-05 US US16/562,349 patent/US11000695B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0473226A (en) * | 1989-07-25 | 1992-03-09 | J Pii U:Kk | Yarn for woven fabric containing far infrared radiation substance and production thereof |
US20040225049A1 (en) * | 2000-05-19 | 2004-11-11 | Toshio Komuro | Composition for far infrared irradiation with excellent antistatic property and fiber and textile product both containing the same |
US20180127903A1 (en) * | 2006-03-29 | 2018-05-10 | Chapman Thermal Products, Inc. | Breathable Fire Resistant Fabrics |
US20130117911A1 (en) * | 2010-07-22 | 2013-05-16 | Robert Bosch Gmbh | Functional underpants for men |
US9408483B2 (en) * | 2012-06-22 | 2016-08-09 | Green Energy Nano Technology Co., Ltd. | Manufacturing method for non-powered energy layer |
US20160353818A1 (en) * | 2015-04-06 | 2016-12-08 | George Psipsikas | Next to skin garments manufactured from a fabric coated with a composite material based on metal oxides and ainorganic material |
US20170135427A1 (en) * | 2015-11-13 | 2017-05-18 | Ap Trennel Limited | Functional fabric and manufacturing method thereof |
US20190009105A1 (en) * | 2016-03-09 | 2019-01-10 | Johnson & Johnson Consumer Inc. | Far infrared radiation heat patch |
US20180305520A1 (en) * | 2017-04-19 | 2018-10-25 | Joy In Biotechnology Co., Ltd. | High content far-infrared elastomer and method of manufacturing the same |
Also Published As
Publication number | Publication date |
---|---|
US20190388704A1 (en) | 2019-12-26 |
US11000695B2 (en) | 2021-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6464245B1 (en) | Underwear to enhance the masculine function of far-infrared fibers | |
Field | Infant massage therapy research review | |
US11000695B2 (en) | Method for treating male sexual dysfunction by using underpants comprising far-infrared fibers | |
Adiga et al. | Intracranial aneurysm and sildenafil | |
CN107405335A (en) | Treat ALS and neuropathic method | |
Finnoff | Some impressions derived from the study of recurrent hemorrhages into the retina and vitreous of young persons | |
Shinkawa et al. | Depressive state and common cold | |
Tattersall | Hypoadrenia or “a bit of Addison's Disease” | |
Chandravanshi et al. | A Critical Clinical Study of Neonatal Jaundice and its Treatment Modalities Through Ayurveda-A Case Study | |
CN112641765B (en) | Anti-fatigue pharmaceutical application of propofol | |
Asghar et al. | Kyzatrex-Oral testosterone replacement therapy | |
HOSSAIN et al. | A pilot study on jimutaka vamana yoga in the management of eka kushta wsr to psoriasis. | |
Ratz et al. | Health problems in geriatric horses | |
Gray | Mastocytoma mischief: activation of a solitary mastocytoma as a sole manifestation of peanut allergy in a child | |
Casson et al. | Cone Rescue with Laser Photobiomodulation in Murine and Human Retinal Dystrophy | |
Rajiah et al. | Psychological impotence: Psychological erectile dysfunction and erectile dysfunction causes, diagnostic methods and management options | |
Ismaili et al. | Nursing Care in Children with Type 1 Diabetes Mellitus | |
Takayama et al. | Acute hyposmia in type 2 diabetes | |
Drouin et al. | A double-blind, placebo-controlled, randomized trial of XP-828L (800 mg) on the quality of life and clinical symptoms of patients with mild-to-moderate psoriasis | |
Sabarinath et al. | An observational study to evaluate the efficacy of Saha Ashwagandhadi Taila Nasya and Balashatavaryadi Ghrita Tarpana in Prathama Patalagata Timira with special reference to Simple Myopia | |
Thapa et al. | Chlorpromazine Induced Cataract in a female patient: A Case Report | |
SHELTON et al. | FUGITIVE ACROMEGALY. ACROMEGALY FOLLOWED BY PITUITARY CACHEXIA TREATMENT WITH AN ALKALINE EXTRACT OF THE ANTERIOR PITUITARY | |
TWM560198U (en) | Far infrared underpants | |
Kimothi | A conceptual review of Matra Basti in children wsr to Cerebral Palsy | |
Vaidya et al. | AN AYURVEDIC MANAGEMENT OF PSORIASIS: A SINGLE CASE STUDY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GREEN ENERGY NANO TECHNOLOGY CO., LTD., TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LIANG, TIEN-SHOW;REEL/FRAME:043919/0101 Effective date: 20170905 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |